Breast Cancer Diagnostics Market Size, Share, Growth, and Industry Analysis, By Type (Imaging,Biopsy,Genomic Tests,Blood Tests,Others), By Application (Hospital,Clinics), Regional Insights and Forecast to 2035

Breast Cancer Diagnostics Market Overview

The global Breast Cancer Diagnostics Market is forecast to expand from USD 6615.45 million in 2026 to USD 7111.61 million in 2027, and is expected to reach USD 12687.48 million by 2035, growing at a CAGR of 7.5% over the forecast period.

The global Breast Cancer Diagnostics Market is estimated at approximately USD 5.48 billion as of 2024. Imaging technologies account for around 51.98 % of the global market share for that year. North America captured roughly 46.60 % of the global market in 2024, making it the largest regional contributor. Diagnostic & predictive applications through breast cancer diagnostics represent nearly 48.69 % of the market in the same year.

Within the United States, the Breast Cancer Diagnostics Market captured an estimated USD 2,261.5 million in 2024, representing approximately 41.3 % of the global market base. The imaging segment in the U.S. held about 51.77 % of the market share in 2024. Digital breast tomosynthesis alone accounted for roughly 49.93 % of the image-based diagnostic segment in 2023 in the U.S. Some 90 % of mammography procedures in the U.S. had transitioned to digital formats by 2021.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

KEY FINDINGS

• Key Market Driver: Imaging segment accounts for approximately 51.98 % share of the global market in 2024.
• Major Market Restraint: Roughly 50 % of diagnostic centres face workforce shortages in radiology imaging services in developed markets.
• Emerging Trends: The blood tests / liquid biopsy segment is showing the fastest growth with under 10 % share but rapidly expanding.
• Regional Leadership: North America region holds about 46.60 % of global market share in 2024.
• Competitive Landscape: Two leading companies hold over 70 % of instrument-based diagnostics product share in 2024.
• Market Segmentation: Diagnostic & predictive application segment occupies ~48.69 % of the global market in 2024.
• Recent Development: Approximately 94 % of advanced breast imaging labs in developed economies have adopted AI-enabled imaging tools by 2025.

Breast Cancer Diagnostics Market Latest Trends

In the broader Breast Cancer Diagnostics Market, the imaging segment dominates with approximately 52 % of global share in 2024. Adoption of digital mammography, tomosynthesis and MRI is widespread in developed markets, while emerging regions accelerate installation of screening infrastructure. The blood tests (liquid biopsy) sub-segment is the fastest-growing type within the market, although it still constitutes under 10 % of the base; the value proposition of minimally invasive circulating tumour DNA (ctDNA) and tumour-marker panels is gaining traction.

Breast Cancer Diagnostics Market Dynamics

The Breast Cancer Diagnostics Market Dynamics are shaped by a combination of technological innovation, disease prevalence, and healthcare infrastructure investment. Rising breast cancer incidence — exceeding 2.3 million global cases annually — continues to propel demand for advanced diagnostics solutions. Imaging remains the core driver, representing nearly 52% of the total diagnostics market. Growing preference for digital mammography and 3D tomosynthesis systems has improved detection accuracy by over 25% compared to conventional technologies. However, workforce shortages in radiology and pathology, estimated at over 40% in developing nations, create bottlenecks in diagnostics capacity.

DRIVER

"Rising demand for advanced imaging diagnostics in breast cancer."

The main growth driver for the Breast Cancer Diagnostics Market is the rising demand for advanced imaging diagnostics for breast cancer detection and diagnosis. With over 310,700 new invasive breast cancer cases in the U.S. alone in 2024, there is strong demand for advanced imaging modalities. Imaging technologies such as digital mammography, tomosynthesis, MRI and ultrasound now cover up to around 90 % of mammography procedures in certain developed markets. The screening programmes in North America and Europe are robust, requiring installation of high-throughput imaging platforms and diagnostic workflows. This large installed base and replacement cycle for equipment is fuelling the market. Providers of imaging hardware, image-guided biopsy tools and diagnostic services benefit significantly from the shift to multi-modality imaging. For B2B stakeholders examining the Breast Cancer Diagnostics Market Research Report and Breast Cancer Diagnostics Industry Report, the driver of advanced imaging remains pivotal.

RESTRAINT

"Workforce shortages and uneven access to imaging diagnostics".

A significant restraint facing the Breast Cancer Diagnostics Market is the shortage of trained imaging personnel and uneven access to diagnostic infrastructure. In the U.S., projections indicate a radiology physician shortage of 10,300 to 35,600 by 2034, which slows procedure volumes and limits capacity for imaging centres. In underserved or rural regions, access to mammography or tomosynthesis remains below 50 % of eligible women, reducing screening penetration and therefore demand for diagnostics services. These limitations impact the Breast Cancer Diagnostics Market because diagnostic reagents and biopsy consumables may face slower uptake when referrals are delayed or screening workflows are underdeveloped. For B2B firms evaluating the Breast Cancer Diagnostics Market Forecast, understanding workforce and infrastructure constraints is critical.

OPPORTUNITY

"Growth in liquid biopsy and genomic-based diagnostics."

One of the major opportunities in the Breast Cancer Diagnostics Market is the growth of liquid biopsy and genomic-based diagnostics for breast cancer. The blood test segment is now recognised as the fastest growing type segment within the breast cancer diagnostics market. Non-invasive assays such as ctDNA, circulating tumour cells and tumour-marker panels for breast cancer are being introduced for early detection, recurrence monitoring and treatment stratification. With increasing demand for personalised medicine and companion diagnostics, genomic testing is becoming a high-potential sub-segment of the Breast Cancer Diagnostics Market. For B2B stakeholders in diagnostics reagents and software, focusing on platform-based genomics and AI-driven interpretation can capture value in this evolving market. The integration of genomic tests with imaging workflows signals a new frontier in the Breast Cancer Diagnostics Market Opportunities.

CHALLENGE

"Reimbursement complexity and high cost of advanced diagnostics."

A key challenge in the Breast Cancer Diagnostics Market is the complexity of reimbursement and the comparatively high cost of advanced diagnostics technologies. While imaging equipment installation is capital-intensive, newer diagnostics such as genomic assays or liquid biopsies often face delays in payer coverage. Data shows that only about half of new diagnostic tests achieve full reimbursement within two years in developed markets, which slows uptake and limits procedure volumes in the Breast Cancer Diagnostics Market. Additionally, delivering diagnostic services in emerging markets often requires lower-cost models and adaptation to local regulatory and reimbursement contexts. For B2B players evaluating the Breast Cancer Diagnostics Market Forecast or Breast Cancer Diagnostics Market Share breakdowns, cost and reimbursement barriers must be factored into adoption assumptions for new diagnostic technologies.

Breast Cancer Diagnostics Market Segmentation

The Breast Cancer Diagnostics Market Segmentation is classified by type and application, covering all diagnostic modalities and end-use environments. By type, the market is divided into Imaging, Biopsy, Genomic Tests, Blood Tests, and Others, each serving a specific diagnostic stage. Imaging leads with approximately 51.98% market share, followed by biopsy procedures contributing around 20%. Genomic tests account for 12%, while blood tests — primarily liquid biopsy — represent nearly 10%. The remaining 6% comprises advanced modalities such as elastography, AI algorithms, and thermal imaging. Each type segment addresses distinct phases of breast cancer detection, confirmation, and monitoring.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

• Imaging: Imaging dominates the Breast Cancer Diagnostics Market, accounting for approximately 51.98% of the global market share in 2024. It includes digital mammography, 3D tomosynthesis, ultrasound, MRI, and PET/CT scans used for detecting breast lesions and classifying abnormalities. More than 90% of mammography systems in advanced markets are now digital, improving diagnostic accuracy by over 25% compared to analog systems. Tomosynthesis and MRI are increasingly utilized in dense breast tissues, where sensitivity levels exceed 90%. Hospitals and diagnostic centers continue upgrading to AI-enhanced image interpretation tools, driving further efficiency across imaging workflows in the Breast Cancer Diagnostics Market worldwide.
• Biopsy: The biopsy segment forms a critical part of the Breast Cancer Diagnostics Market, representing around 20% of the total diagnostic procedures globally. Biopsy tests—such as fine-needle aspiration, core needle biopsy, and vacuum-assisted biopsy—remain essential for confirming malignancy and receptor status evaluation. The global demand for image-guided biopsies is growing rapidly, with over 60% of hospitals now using ultrasound or stereotactic guidance systems for precision targeting. Innovations in biopsy needles and vacuum-assisted systems have increased tissue sampling accuracy by more than 15% in the past five years. As pathology labs expand, biopsy demand strengthens across all healthcare tiers.
• Genomic Tests: Genomic tests hold a rapidly expanding position in the Breast Cancer Diagnostics Market, representing about 12% of the total diagnostic landscape in 2024. These tests analyze genetic mutations such as BRCA1/2, HER2, and multi-gene panels to assess recurrence risks and therapy response rates. The utilization of genomic profiling has improved treatment precision by over 40% in hormone-receptor-positive and triple-negative breast cancer patients. Growing awareness of hereditary cancer syndromes has driven testing volumes, particularly among women under 45. Integration of genomic data into personalized treatment pathways supports the evolution of precision oncology, creating strong opportunities for genomics-based diagnostics.
• Blood Tests (Liquid Biopsy): The blood test or liquid biopsy segment is the fastest-growing type within the Breast Cancer Diagnostics Market, currently holding around 8–10% of the total market share. This non-invasive approach detects circulating tumor DNA (ctDNA) and tumor cells for early-stage diagnosis and post-treatment monitoring. Liquid biopsy tests have achieved sensitivity levels exceeding 85% and specificity above 90% in several clinical settings. The growing demand for painless, cost-effective diagnostics has accelerated adoption among both hospitals and reference labs. As clinical validation increases, liquid biopsy is projected to replace up to 20% of conventional tissue biopsies by 2030 globally.
• Others: The “Others” category in the Breast Cancer Diagnostics Market comprises supplementary diagnostic modalities such as thermal imaging, elastography, AI-based diagnostic algorithms, and advanced immunohistochemistry assays. Although this segment represents roughly 6–8% of the total market share, it is gaining importance as healthcare providers adopt complementary tools to enhance diagnostic precision. AI-driven algorithms can reduce false positives by up to 30%, while elastography and optical imaging technologies improve tissue differentiation accuracy by nearly 20%. Integration of these innovations into existing imaging and pathology workflows offers cost-efficient diagnostic support and strengthens real-time decision-making across healthcare networks.

BY APPLICATION

• Hospitals & Clinics: Hospitals and clinics account for approximately 50% of the global Breast Cancer Diagnostics Market share in 2024, representing the largest end-use segment. These facilities provide comprehensive diagnostic pathways including screening, imaging, biopsy, pathology, and genomic testing. Over 85% of hospital-based diagnostic centers are equipped with digital mammography and tomosynthesis systems, enabling faster detection and workflow efficiency. In addition, more than 60% of oncology hospitals integrate AI-powered software to interpret breast imaging scans and improve accuracy in early-stage detection. Hospitals also serve as referral hubs for genomic and molecular testing, driving consistent demand across developed and emerging healthcare ecosystems.
• Diagnostic Centres & Medical Laboratories: Diagnostic centres and medical laboratories hold around 35–40% of the Breast Cancer Diagnostics Market, serving as decentralized facilities for imaging, pathology, and molecular testing. These centres handle large test volumes, processing up to 65% of biopsy and genomic samples from outpatient referrals. The expansion of private diagnostic networks has increased access to breast cancer testing by nearly 30% in urban regions since 2020. Medical laboratories are also major adopters of liquid biopsy technologies and next-generation sequencing (NGS) workflows, offering faster turnaround times of less than 48 hours for genomic reports. Their scalable infrastructure supports precision diagnostics growth globally.

Regional Outlook for the Breast Cancer Diagnostics Market

The Regional Outlook of the Breast Cancer Diagnostics Market demonstrates significant geographic diversity in adoption patterns, diagnostic infrastructure, and healthcare readiness. North America dominates the global market, accounting for approximately 46.60% of total share in 2024. The United States alone represents 41.3%, supported by widespread use of digital mammography (over 90%) and advanced genomic testing. High patient awareness and robust screening programs strengthen this regional position.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

The North America region captured around 46.60 % of the global Breast Cancer Diagnostics Market share in 2024. The United States alone accounted for approximately 41.3 % of the global breast cancer diagnostics market in 2024 with an estimated market size of USD 2,261.5 million. High incidence of breast cancer cases (over 310,700 new invasive cases in the U.S. in 2024) has driven adoption of advanced diagnostics. Over 90 % of mammography procedures in the U.S. are digital, and approximately 49.93 % of image-based diagnostics in 2023 were digital breast tomosynthesis. Installation of next-generation imaging modalities and increasing adoption of genomic and liquid biopsy technologies further underpin the market.

The North America Breast Cancer Diagnostics Market is estimated at USD 2,750.6 million in 2025, representing 44.7% of global share, and is projected to reach USD 5,026.4 million by 2034, expanding at a CAGR of 7.2%. This regional growth is primarily driven by technological advancements in digital mammography, widespread adoption of AI-driven image analysis tools, and growing screening rates among women aged 40–70.

North America – Major Dominant Countries in the Breast Cancer Diagnostics Market

• United States: The U.S. market size is USD 2,140.6 million in 2025, holding 34.8% share, expected to hit USD 3,876.2 million by 2034 with a CAGR of 7.4%, driven by advanced imaging adoption and genetic testing expansion.
• Canada: The Canadian market stands at USD 340.2 million in 2025, capturing 5.5% share, projected to reach USD 637.1 million by 2034 at a CAGR of 7.2%, propelled by early screening programs and cross-border technology imports.
• Mexico: Mexico’s market size is USD 145.8 million in 2025, accounting for 2.4% share, likely to touch USD 278.6 million by 2034 with a CAGR of 7.5%, supported by hospital modernization and breast imaging expansion.
• Cuba: The Cuban diagnostics market totals USD 52.3 million in 2025, comprising 0.8% share, projected to reach USD 98.5 million by 2034 with 7.3% CAGR, as screening facilities expand under national oncology programs.
• Puerto Rico: Estimated at USD 71.7 million in 2025 with 1.1% share, the Puerto Rican market is forecast to hit USD 135.9 million by 2034 at 7.1% CAGR, driven by diagnostic imports and public–private partnerships.

EUROPE

In Europe, the Breast Cancer Diagnostics Market is supported by strong national screening programmes and technological adoption. For instance, the UK held approximately 14.31 % of Europe’s market in 2024. Germany records about 78,000 new breast cancer cases annually, making it the most common female cancer in that country; this level of incidence supports diagnostics demand. Advanced imaging modalities such as tomosynthesis and MRI are increasingly used in German screening – e.g., Germany’s Mammography Screening Programme screens over 3 million women annually, leading to an estimated 25 % reduction in breast cancer mortality. Public-health driven reimbursement in many European countries enables broad adoption of screening and diagnostics, providing large volume for providers in the Breast Cancer Diagnostics Market.

The Europe Breast Cancer Diagnostics Market is projected at USD 1,785.8 million in 2025, constituting 29.0% global share, and expected to reach USD 3,356.1 million by 2034, growing at a CAGR of 7.4%. Europe remains a key contributor, driven by structured breast screening programs, advanced genomic testing adoption, and expanding diagnostic laboratories across major economies. Countries such as Germany, France, and the United Kingdom maintain strong reimbursement frameworks and early detection strategies, resulting in one of the world’s highest diagnostic coverage rates for women over 40 years of age.

Europe – Major Dominant Countries in the Breast Cancer Diagnostics Market

• Germany: Market size USD 482.6 million in 2025, with 7.8% global share, rising to USD 915.3 million by 2034 at 7.5% CAGR, driven by high screening participation and precision diagnostics implementation.
• United Kingdom: Valued at USD 361.4 million in 2025, holding 5.9% share, expected to reach USD 684.7 million by 2034 with 7.3% CAGR, supported by the NHS digital breast screening expansion.
• France: Market size USD 312.7 million in 2025, capturing 5.1% share, forecasted to achieve USD 597.9 million by 2034, growing at 7.5% CAGR, influenced by integrated hospital diagnostic systems and public awareness campaigns.
• Italy: Estimated at USD 251.9 million in 2025, with 4.1% share, projected to reach USD 474.3 million by 2034 at a CAGR of 7.6%, supported by AI-assisted mammography adoption.
• Spain: The Spanish market totals USD 202.3 million in 2025, making up 3.3% share, forecast to reach USD 377.2 million by 2034 at a CAGR of 7.4%, fueled by healthcare digitization and regional screening expansion.

ASIA-PACIFIC

In the Asia-Pacific region, the Breast Cancer Diagnostics Market shows the fastest growth potential due to rising breast cancer incidence, expanding healthcare infrastructure and increased screening awareness. China reported 357,161 new breast cancer cases in 2022 (age-standardised rate of 33 per 100,000 women) and projections indicate this could rise above 480,000 by 2040. Japan recorded 91,916 new cases in 2022 at an ASR of 74.4 per 100,000 women. Increased government screening initiatives and adoption of digital mammography and tomosynthesis support market growth in Asia-Pacific.

The Asia Breast Cancer Diagnostics Market is valued at USD 1,122.5 million in 2025, accounting for 18.2% of the global share, and is forecast to reach USD 2,248.6 million by 2034, expanding at a CAGR of 8.0%. Rapid urbanization, an increasing female population base, and growing adoption of early screening programs are the primary factors fueling market growth across Asia.

Asia – Major Dominant Countries in the Breast Cancer Diagnostics Market

• China: Market size USD 436.9 million in 2025, representing 7.1% share, projected to reach USD 918.2 million by 2034 at 8.2% CAGR, driven by large-scale national screening and digital imaging expansion.
• Japan: The Japanese market totals USD 265.3 million in 2025, holding 4.3% share, forecast to reach USD 518.4 million by 2034, growing at 7.8% CAGR, supported by advanced genomic testing utilization.
• India: Valued at USD 203.5 million in 2025, accounting for 3.3% share, expected to reach USD 422.6 million by 2034 with 8.4% CAGR, driven by expanding private diagnostic networks.
• South Korea: Market size USD 128.7 million in 2025, with 2.1% share, likely to reach USD 266.4 million by 2034, expanding at 8.1% CAGR, due to high adoption of breast imaging AI systems.
• Australia: Estimated at USD 88.1 million in 2025, representing 1.4% share, expected to hit USD 182.9 million by 2034 with 8.0% CAGR, boosted by preventive healthcare programs and clinical genomics testing expansion.

Middle East & Africa (MEA)

In the Middle East & Africa region, the Breast Cancer Diagnostics Market is expanding gradually as breast cancer incidence rises and healthcare infrastructure improves. In South Africa, 71,861 breast cancer cases were diagnosed in 2022. Several countries, including Saudi Arabia, UAE and Morocco, have launched organised screening programmes and partnerships with firms developing AI-enabled diagnostics. For example, Saudi Arabia’s health ministry and a national AI authority launched an early breast cancer screening platform in 2022.

The Middle East and Africa Breast Cancer Diagnostics Market is valued at USD 495.0 million in 2025, accounting for 8.0% global share, and projected to reach USD 1,004.2 million by 2034, growing at a CAGR of 8.2%. Increasing government-backed screening programs, rising breast cancer prevalence, and rapid growth of diagnostic centers are key factors supporting expansion. The region’s adoption of AI-assisted imaging systems and liquid biopsy diagnostics is improving early detection rates and creating new opportunities for market players.

Middle East and Africa – Major Dominant Countries in the Breast Cancer Diagnostics Market

• Saudi Arabia: Market size USD 134.8 million in 2025, holding 2.2% share, expected to reach USD 277.4 million by 2034, growing at 8.3% CAGR, supported by national screening initiatives and digital healthcare investments.
• United Arab Emirates: Valued at USD 88.5 million in 2025, accounting for 1.4% share, projected to hit USD 181.2 million by 2034, expanding at 8.2% CAGR, driven by public-private diagnostic collaborations.
• South Africa: The market totals USD 71.4 million in 2025, representing 1.2% share, likely to reach USD 146.3 million by 2034, recording 8.4% CAGR, as imaging capacity increases across major cities.
• Egypt: Estimated at USD 56.9 million in 2025, capturing 0.9% share, forecast to reach USD 117.9 million by 2034, growing at 8.5% CAGR, driven by awareness and diagnostic center expansion.
• Nigeria: Market size USD 41.5 million in 2025, with 0.7% share, projected to reach USD 81.4 million by 2034, expanding at 8.1% CAGR, supported by healthcare funding for early cancer detection.

List of Top Breast Cancer Diagnostics Companies

• Hologic, Inc.
• Myriad Genetics, Inc.
• Koninklijke Philips N.V.
• Becton, Dickinson and Company
• Danaher
• Genomic Health
• NanoString Technologies, Inc.
• Devicor Medical Products, Inc.
• R. Bard, Inc.

Hologic, Inc.: holds leading market share in breast imaging equipment and diagnostics within the Breast Cancer Diagnostics Market; instrument-based product share around 70 % in 2024.

Myriad Genetics, Inc.: holds leading market share in genomic risk and recurrence testing within the Breast Cancer Diagnostics Market, especially for hereditary breast cancer assessment.

Investment Analysis and Opportunities

Investment in the Breast Cancer Diagnostics Market is being driven by the need to scale imaging capacity, upgrade ageing mammography fleets and integrate advanced diagnostics such as genomics and liquid biopsy. With imaging representing around 52 % of global market share in 2024, significant capital is directed toward manufacturers of tomosynthesis units, MRI/ultrasound systems and AI-enabled workflow platforms. The blood-test diagnostics (liquid biopsy) segment, although still under 10 % of the market, is identified as the fastest growing type segment, offering a strong opportunity for reagent and service providers. For B2B service providers and diagnostics reagent firms, partnering with hospital networks (which account for around 50 % of end-use share) offers a route to scale.

The shift toward personalised diagnostics and precision oncology means genomics test providers are well-positioned; bundling genomic assays with imaging and biopsy workflows enhances value proposition and drives differentiation in the Breast Cancer Diagnostics Market. In emerging regions such as Asia-Pacific and MEA, investment opportunities exist in building screening infrastructure, diagnostic centres and mobile imaging units; these regions are projected to record higher growth rates over the forecast period. Nonetheless, investors must account for reimbursement timelines, regulatory entry and workforce constraints when evaluating opportunities in the Breast Cancer Diagnostics Market Research Report. For diagnostics companies, favourable returns may be realised by focusing on asset-lite diagnostic service models, integrated imaging/biopsy/genomic offerings and collaborations with large hospital systems – essential strategies to capture value within the Breast Cancer Diagnostics Market Share landscape.

New Product Development

New product development in the Breast Cancer Diagnostics Market is gaining momentum across multiple modalities. Imaging device manufacturers are launching next-generation digital breast tomosynthesis systems with automated breast volume scanning (ABVS) to improve detection accuracy in dense breast tissue – addressing the dominant imaging segment (~52 % share). Genomic diagnostics firms are introducing multi-gene panels and AI-based interpretation platforms to deliver recurrence risk scores and hereditary risk stratification, thereby strengthening their positioning within the Breast Cancer Diagnostics Market. Liquid biopsy tests that detect circulating tumour DNA (ctDNA) are now being introduced for minimal residual disease monitoring and early detection; this taps into the rapidly growing blood-test segment of the Breast Cancer Diagnostics Market.

Vendors are also releasing integrated workflow software that connects imaging, biopsy, pathology and genomics into a unified diagnostic pathway for breast cancer, simplifying adoption by hospitals & clinics (which represent approximately 50 % of end-use). For B2B buyers in the Breast Cancer Diagnostics Market, new offerings include remote reading services, AI-enabled image interpretation, cloud-based genomics and portable imaging systems targeted at screening in emerging markets. The pace of innovation suggests that suppliers who can bundle hardware, molecular diagnostics and analytics will capture higher value across the Breast Cancer Diagnostics Market.

Five Recent Developments

• In March 2024, a major healthcare company launched a new all-in-one AI application platform comprising three modules (DBT-based, 2D mammography and density assessment) to support breast cancer detection and workflow efficiency within the Breast Cancer Diagnostics Market.
• In August 2024, a device company announced regulatory submission strategy for a breast computed tomography imaging system targeting dense breast tissue in the U.S. and EU markets, enhancing imaging segment capabilities in the Breast Cancer Diagnostics Market.
• In February 2025, a diagnostics firm launched a blood-test specifically for high-density breast tissue detection with demonstrated sensitivity of 90 % and specificity of 85.5 %, signalling growth of liquid biopsy segment in the Breast Cancer Diagnostics Market.
• In February 2025, reimbursement criteria for a genomic test for early-stage HR+/HER2- negative breast cancer in Belgium were expanded to include neoadjuvant treatment settings, increasing access for genomic diagnostics in the Breast Cancer Diagnostics Market.
• In June 2023, a major diagnostics company partnered with a pharmaceutical firm to enhance next-generation sequencing (NGS) testing for breast and lung cancer patients, building genomics capabilities across the Breast Cancer Diagnostics Market.

Report Coverage of Breast Cancer Diagnostics Market

The research report titled Breast Cancer Diagnostics Market Report provides comprehensive coverage of market size, share, segmentation, competitive landscape, trends, growth drivers and opportunities within the breast cancer diagnostics field. The report covers historical data from 2021-2023 and includes forecasts to 2033 (or 2034 depending on the source) for multiple regions including North America, Europe, Asia-Pacific and Middle East & Africa. According to segmentation analysis, the report includes type-wise breakdown (Imaging, Biopsy, Genomic Tests, Blood Tests, Others) and application analysis (Screening, Diagnostic & Predictive, Prognostic, Research) with end-use breakdown (Hospitals & Clinics, Diagnostic Centres & Medical Laboratories).

Breast Cancer Diagnostics Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 6615.45 Million in 2026
Market Size Value By	USD 12687.48 Million by 2035
Growth Rate	CAGR of 7.5% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Imaging Biopsy Genomic Tests Blood Tests Others By Application : Hospital Clinics
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample